Daily Archives: December 18, 2018

The North American Bitcoin Conference Stands Out as One of 2019’s Most Important Worldwide Crypto Events

MIAMI, Dec. 18, 2018 (GLOBE NEWSWIRE) — via CryptoCurrencyWire – 2019 will kick off with what has become widely accepted as one of the most important blockchain conferences of the year. The North American Bitcoin Conference, sponsored by Keynote and part of the World Blockchain Forum, will take place Jan. 16-18, 2019, at the James L. Knight Center in Miami, Florida. This premier crypto conference, now in its seventh year, will draw cryptocurrency and blockchain leaders from all across the globe as they come together for this historical event.

The North American Bitcoin Conference is the longest-running, most-attended finance conference for the blockchain and crypto industries, with each event attracting thousands of attendees. The 2019 conference will feature a lineup of more than 60 world-class presenters, including technology veterans and company founders who have collectively raised more than $18.1 billion in initial coin offerings (ICOs).

Speakers that have been announced thus far include:

  • David Chaum, inventor of digital cash
  • Dr. Patrick Byrne, founder of Overstock.com and t0
  • Halsey Minor, founder of CNET
  • Veronica McGregor, head of legal at Shapeshift.io
  • Matthew Roszak, co-founder of Bloq
  • Charlie Shrem, Bitcoin pioneer
  • Maja Vujinoc, CEO at OGroup
  • Craig Sellars, co-founder of Tether
  • Jason King, co-founder of Academy
  • Bruce Fenton, president of Atlantic Financial
  • Epperly Li, investment director at Bitmain
  • Marco Santori, president of Blockchain.com
  • Andrew Filipowski, chairman of Tally Capital
  • Sang Lee, president & CEO of Darcmatter
  • Alexa Hefti, blockchain tax lead at Deloitte
  • Jeffrey Tucker, editorial director at American Institute for Economic Research

Above and beyond the robust array of speakers and sponsors, the conference will include brand-new Lightning Networking sessions and creative installments. An added focus for January’s conference will be a dedicated Security Tokens track, unpacking the new frontier that has combined securities and blockchain technology. Mainstay topics discussed at the conference will include investments, legal implications and regulations, the way decentralization is disrupting multiple industries, and successful ICOs of the past and present.

Tickets for The North American Bitcoin Conference Miami are available at https://btcmiami.com/tickets.

Past crypto-assets that have been launched concurrent with The North American Bitcoin series of conferences include:

  • Ethereum, launched in August 2014 at The North American Bitcoin Conference Chicago
  • Dash, launched in January 2016 at The North American Bitcoin Conference Miami
  • Litecoin, launched in August 2013 at The European Blockchain Conference
  • Factom, launched in January 2016 at The North American Bitcoin Conference Miami

Keynote, the sponsoring organization of The North American Bitcoin Conference, is a premier provider of world-class events for the blockchain industry. The Keynote team desires to provide conference attendees with valuable opportunities to meet influential individuals in the crypto space, learn about new products and investment opportunities, discuss white papers, and gain a better understanding about the quickly expanding world of blockchain. Speakers, exhibitors and sponsors attending The North American Bitcoin Conference represent some of the greatest blockchain companies and experts in the space.

The North American Bitcoin Conference Contact:
Online contact form: https://btcmiami.com/contact-us/
Sponsorship and exhibiting information: amy@keynote.ae
Media inquiries: amandah@keynote.ae

Corporate Communications Contact:
CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.418.1217 Office
Editor@CryptoCurrencyWire.com

Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

– Seasoned biotech executive and accomplished scientific leader with broad experience from early-stage company development to managing publicly traded entities –

GERMANTOWN, Md., Dec. 18, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, appointed Kenneth C. Carter, Ph.D., as the Company’s Executive Chairman of the Board to be effective on January 1, 2019. Dr. Carter will replace interim CEO, Jim Scully, who will be stepping down.

“Dr. Carter brings a wealth of drug development expertise and executive leadership having led both private and public biotechnology companies. His leadership will be invaluable to Neuralstem at a critical juncture in the Company’s evolution,” said William Oldaker, Chairman of the Board. “Our team will greatly benefit from Dr. Carter’s entrepreneurial background with development stage companies. On behalf of the Board, I would like to thank Jim for his guidance during this transition period.”

“I look forward to working with the team at Neuralstem to develop and execute on a strategic plan to deliver on promising therapies and maximize value for shareholders,” said Dr. Ken Carter.

Dr. Carter is a dynamic industry executive and scientific leader with deep experience in development-stage biotechnology companies. Over the past decade, he has helped found and lead several companies including NexImmune, Inc., an immuno-oncology company which he helped spin out from John Hopkins University and served as CEO from inception in 2011 until June 2017. He also co-founded and is currently Chairman of the Board of Noble Life Sciences, Inc, a pre-clinical contract research organization that enables translational science and product development for biotechnology and pharmaceutical companies. Dr. Carter was also co-founder and CEO of Avalon Pharmaceuticals from inception in 1999 until the Company’s merger with Clinical Data in 2009 and led Avalon’s initial public offering on the NASDAQ stock exchange in 2004. Under Dr. Carter’s leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology and successfully secured R&D partnerships with Merck, Novartis, Sanofi-Aventis and MedImmune.

Dr. Carter has served on numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics, Inc., Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI). He is also an adjunct faculty member at John Hopkins University. He completed a postdoctoral fellowship in Cell Biology at the University of Massachusetts Medical School. He received his doctoral degree in Human Genetics and Cell Biology at the University of Texas Medical Branch at Galveston and his B.S. at Abilene Christian University.

Inducement Grant

In connection with Dr. Carter’s employment, on December 12, 2018, the Compensation Committee of the company’s Board of Directors approved the grant of a non-qualified inducement stock option to purchase 800,000 shares of the company’s common stock.  The option has an exercise price of the $0.425 (the closing price of the common stock on the date of grant), a term of ten (10) years, and vests as follows: (i) 200,000 of the stock options vest on the effective date of employment, (ii) 100,000 of the stock options vest on the six month anniversary of the effective date of employment, (iii) 100,000 of the stock options vest on the two year anniversary of the effective date of employment, and (iv) 400,000 of the stock options vest upon the achievement of certain performance-based milestones to be agreed upon by the Company and Dr. Carter.

About Neuralstem

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. Neuralstem’s diversified portfolio of product candidates includes its proprietary neural stem cell technology.

The Company has two lead development candidates:

  • NSI-566 is a neural stem cell therapy in clinical development for treatment of paralysis in stroke, for Amyotrophic Lateral Sclerosis (ALS) and for chronic spinal cord injury (cSCI).
  • NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

Cautionary Statement Regarding Forward Looking Information

This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2017, and its Quarterly Report on Form 10-Q for the three, six and nine months ended March 31, June 30 and September 30, 2018, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact:
Investors:
Argot Partners (Investor Relations)
212-600-1902
neuralstem@argotpartners.com

Family of Constant-Current Dimmable Buck LED Drivers

1.5A, 3A Buck LED Drivers Target ISO26262 automotive and industrial applications

MILPITAS, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) — AMS, the Analog Mixed-Signal division of ISSI, has introduced a family of switching buck LED Drivers for automotive and industrial applications. This family of highly integrated switching constant current buck LED Drivers are targeted for 12V/24V battery connected, space-constrained, electromagnetic (EMC) sensitive applications such as Headlight, Front and Rear Fog lights, Day time Running lights to name a few.Family of Automotive & Industrial LED Drivers

The device family supports a wide DC voltage input range of 4.5V to 38V and outputs a 5% regulated current of 1.5A or 3A; depending on the particular device, see table.  The integrated power MOSFET is configured to switch in the constant on-time mode delivering true average current.  Switching at a frequency of up to 2MHz which is adjustable with an external resistor, these buck LED Drivers can use smaller output inductor and capacitor values thereby reducing total size and cost.  The frequency adjust capability allows the designer flexibility in selecting the optimum switching frequency to avoid disrupting the AM broadcast or sensitive vehicle RF components.

The family of switching regulators also features a spread spectrum function to modulate the internal oscillator about the configured operating frequency.  This modulation or dithering of the frequency will optimize EMI (Electromagnetic Interference) to spread the total electromagnetic emitting energy into a wider range that significantly degrades the peak energy of EMI.  With spread spectrum, EMI tests can be passed with a smaller size and lower cost filter circuit.

The devices come in a small space-saving and thermally enhanced SOP-8-EP package.  An external control pin accepts a PWM signal to enable the dimming of high brightness LEDs. Comprehensive protection against possible fault conditions caused by short or open circuits is also included, along with over-temperature protection.  “Our feature rich family of buck LED drivers are optimized for ease of system design and improved system reliability in critical automotive lighting applications such as Headlights, DRL’s, and Front and Rear Fog Lamps,” remarked Venkatesh Shan, VP of Analog Products at ISSI.  “Our family of high power LED drivers provide the notification of a fault condition so as to adhere to the ISO 26262 standard for functional safety in road vehicles.”

4.5~38V Buck LED Regulator PWM Dimmable
Part Number AEC-Q100 LED Current Fault Report Spread Spectrum
 IS32LT3951 Y 1.5A Y Y
 IS32LT3952 Y 1.5A N Y
 IS32LT3953 Y 3A N Y
 IS32LT3954 Y 3A Y Y
 IS31LT3952 N 1.5A N Y
 IS31LT3953 N 3A N Y
 IS31LT3954 N 3A Y Y
 IS31LT3954A N 3A Y (shared) Y

Table 1 Family of Constant-Current PWM Dimmable Buck Regulator LED Drivers

The IS32LT3951, IS32LT3952, IS32LT3953 and IS32LT3954 are all AEC-Q100 qualified and Production Part Approval Process (PPAP) capable. The IS31LT3952, IS31LT3953, IS31LT3954, IS31LT3954A are lower cost versions for non-automotive industrial applications with pricing starting at $0.33 for quantities of 100K for the IS31LT3952. For pricing on the rest of the family contact ISSI Sales.

For more information on AMS LED products, visit the AMS Analog products website at
ams.issi.com/US/product-analog-hbled-driver.shtml

About AMS
AMS is the analog mixed signal division of ISSI, a fabless semiconductor company that designs and markets high performance integrated circuits for the following key markets: (I) automotive, (ii) communications, (iii) industrial/medical, and (iv) digital consumer. AMS’ primary products are LED drivers for low to mid-power RGB color mixing and high power lighting applications.  Other products include audio, sensor and micro controller MCU semiconductor ICs.  ISSI/AMS is headquartered in Silicon Valley with worldwide offices in Taiwan, Japan, Singapore, China, Europe, Hong Kong, India, and Korea. Visit our web site at http://ams.issi.com/

Contact:

Venkatesh Shan, VP of Analog Products, 408-969-4622

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/278a66f8-54fd-4900-b012-1b1f60723f4f

LeddarTech Selects BlackBerry’s QNX Operating System for its Auto and Mobility LiDAR Platform

 The QNX OS for Safety runs the software at the core of LeddarTech’s innovative automotive LiDAR development platform that enables the design of differentiated LiDAR solutions tailored to specific autonomous driving applications.

QUEBEC CITY, Dec. 18, 2018 (GLOBE NEWSWIRE) — LeddarTech, an industry leader providing the most versatile, scalable Auto and Mobility LiDAR Platform, today announced it has selected the QNX OS for Safety as the operating system for its LeddarSP Digital Signal Processing library. The LeddarSP software works in tandem with LeddarCore systems-on-chip to form the LeddarEngine, which is embedded at the heart of a variety of LiDAR sensor designs that enable ADAS and autonomous driving applications.

“We believe that there is no safety without security,” said Grant Courville, VP of QNX Product Management and Strategy at BlackBerry. “We are thrilled to provide LeddarTech, an industry leader in LiDAR technology, with the reliable foundation necessary for building competitive automotive and mission-critical systems in a safe and cost-effective manner.”

“LeddarTech selected BlackBerry as the supplier for the operating system of its LeddarEngine due to the QNX OS for Safety’s capabilities to offer the most advanced and secure embedded operating system developed for use in safety and mission-critical applications, such as ADAS and autonomous driving,” said Antonio Polo, Vice-President of Engineering at LeddarTech. “Customers who opt for our LeddarEngine solution can accelerate their time to market by using the QNX OS for Safety operating system to run LeddarTech’s patented signal-processing algorithms, which enables Tier-1 suppliers and system integrators to design the differentiated LiDAR solutions they need to meet the specific requirements of various automotive and mobility applications.”

The QNX OS for Safety 2.0 is certified to ISO 26262 at ASIL D and IEC 61508 SIL3 by TÜV Rhineland, an international leader in the sustained development of safety and quality.

About LeddarTech
LeddarTech is an industry leader providing the most versatile and scalable Auto and Mobility LiDAR Platform based on the unique LeddarEngine, which consists of a suite of automotive-grade, functional safety certified SoCs working in tandem with LeddarSP signal processing software. The company is responsible for several innovations in cutting-edge mobility remote-sensing applications, its patented technologies enhancing ADAS and autonomous driving capabilities for automobiles, trucks, buses, delivery vehicles, robotaxis, shuttles, and more. Additional information about LeddarTech is accessible at www.LeddarTech.com, and on LinkedIn, Twitter, Facebook and YouTube.

LeddarTech, Leddar, LeddarEngine, LeddarSP, and LeddarTech logos are trademarks or registered trademarks of LeddarTech Inc. All other brands, product names and marks, including BlackBerry, BlackBerry Secure, and QNX OS for Safety, are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

LeddarTech Contact: Daniel Aitken, VP Marketing and Communications
+1-418-653-9000 ext. 232
Daniel.Aitken@Leddartech.com